Literature DB >> 7277093

Complications and sequelae of meningococcal infections in children.

M S Edwards, C J Baker.   

Abstract

Eight-six children with meningococcal meningitis or bacteremia were evaluated prospectively between 1977 and 1979 to determine the incidence of complications and features predictive of their development. The majority (83%) of these infections were caused by serogroup B strains. Twenty-seven percent of survivors experienced one or more suppurative, allergic, or neurologic complications. Hearing loss, noted in 9% of children, occurred significantly more often in patients with admission leukocytosis or leukopenia, or with CSF leukocytosis greater than 10,000/mm3 than in those with an uncomplicated course (P less than 0.01). Ten percent of survivors developed allergic complications manifested as cutaneous vasculitis or arthritis with onset five to eight days after admission. Shock, purpuric skin lesions, and fever persisting longer than five days occurred significantly more often in these children than in those who developed hearing loss or those with an uncomplicated course (P less than 0.05). Resolution of allergic complications occurred within 14 days of their onset. Compared to Neisseria meningitidis groups A and C, group B strains appear to be intermediate in their potential for allergic complications associated with childhood infection.

Entities:  

Mesh:

Year:  1981        PMID: 7277093     DOI: 10.1016/s0022-3476(81)80250-8

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  24 in total

Review 1.  The immunopathogenesis of meningococcal disease.

Authors:  A J Kvalsvig; D J Unsworth
Journal:  J Clin Pathol       Date:  2003-06       Impact factor: 3.411

Review 2.  Hearing impairment after bacterial meningitis: a review.

Authors:  H M Fortnum
Journal:  Arch Dis Child       Date:  1992-09       Impact factor: 3.791

3.  Hospital-based surveillance of meningococcal meningitis in Salvador, Brazil.

Authors:  Soraia M Cordeiro; Alan B Neves; Cássio T Ribeiro; Maya L Petersen; Edilane L Gouveia; Guilherme S Ribeiro; Tatiana S Lôbo; Joice N Reis; Kátia M Salgado; Mitermayer G Reis; Albert I Ko
Journal:  Trans R Soc Trop Med Hyg       Date:  2007-08-06       Impact factor: 2.184

Review 4.  Prospects for vaccine prevention of meningococcal infection.

Authors:  Lee H Harrison
Journal:  Clin Microbiol Rev       Date:  2006-01       Impact factor: 26.132

Review 5.  Update on meningococcal disease with emphasis on pathogenesis and clinical management.

Authors:  M van Deuren; P Brandtzaeg; J W van der Meer
Journal:  Clin Microbiol Rev       Date:  2000-01       Impact factor: 26.132

6.  Cost-utility analysis of a nationwide vaccination programme against serogroup B meningococcal disease in Israel.

Authors:  Gary M Ginsberg; Colin Block; Chen Stein-Zamir
Journal:  Int J Public Health       Date:  2016-04-22       Impact factor: 3.380

7.  Invasive meningococcal disease in children in Greece: comparison of serogroup A disease with disease caused by other serogroups.

Authors:  M N Tsolia; M Theodoridou; G Tzanakaki; V Vlachou; G Mostrou; F Stripeli; P Kalabalikis; A Pangalis; D Kafetzis; J Kremastinou; A Konstantopoulos
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-07       Impact factor: 3.267

8.  Safety and immunogenicity of meningococcal ACWY CRM197-conjugate vaccine in children, adolescents and adults in Russia.

Authors:  Natalia Ilyina; Susanna Kharit; Leila Namazova-Baranova; Asmik Asatryan; Mayya Benashvili; Elmira Tkhostova; Chiranjiwi Bhusal; Ashwani Kumar Arora
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

9.  Immunogenicity of the meningococcal polysaccharide conjugate vaccine in pediatric kidney transplant patients.

Authors:  Delphine R Nelson; Jeffrey Fadrowski; Alicia Neu
Journal:  Pediatr Nephrol       Date:  2018-03-20       Impact factor: 3.714

Review 10.  Immune complex associated complications in the subacute phase of meningococcal disease: incidence and literature review.

Authors:  C A Goedvolk; I A von Rosenstiel; A P Bos
Journal:  Arch Dis Child       Date:  2003-10       Impact factor: 3.791

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.